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Background: Orally inhaled corticosteroids represent the usually recommended initial
controller therapy for most patients with persistent asthma. Some patients might benefit
from earlier use of a combination of an inhaled corticosteroid and an orally inhaled long-
acting b agonist, however. We wished to identify clinical characteristics of patients which
would enable one to identify a sub-group of patients who would benefit most from
initiating sustained controller therapy with combination therapy.
Methods: We carried out a secondary analysis of five randomized clinical trials including
1606 subjects in order to examine whether differences in baseline characteristics of
patients might predict a greater preferential response to combination therapy with
salmeterol and fluticasone.
Results: Subjects whose asthma had been present for 10 or more years were 2.2 times
more likely to achieve well-controlled asthma by 12 weeks on combination therapy, while
subjects with a shorter duration of asthma were only 1.4 times as likely to achieve asthma
control with combination therapy as opposed to inhaled corticosteroids alone. None of the
other factors examined including symptom frequency or severity, rescue b-agonist use,Elsevier Ltd. All rights reserved.
x; CI, confidence interval; FEV1, forced expiratory volume in the first second; ICS, orally inhaled
ng-acting b2 agonist bronchodilator; mg, micrograms; PEF, peak expiratory flow rate; SABA, short-acting
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P. Ernst et al.78severity of lung function impairment or degree of reversibility, was able to distinguish
subjects who would benefit preferentially from such combination therapy.
Conclusions: Longer duration of asthma might be used to identify subjects who will
benefit more from combined maintenance therapy with a long-acting b agonist and an
inhaled corticosteroid rather than an inhaled corticosteroid alone.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Orally inhaled corticosteroids (ICS) are the preferred
maintenance therapy in asthma.1 ICS address the underlying
inflammatory process and result in a rapid reduction in
symptoms and improvement in lung function, although their
full benefit takes several months to achieve.2 When
patients’ asthma is not well controlled on low to moderate
doses of inhaled corticosteroids, several trials have now
conclusively demonstrated that adding an orally inhaled
long-acting b2 agonist bronchodilator (LABA) provides
superior asthma control to that obtained by increasing the
dose of inhaled corticosteroid, even if the dose increase is
four fold.3–6
It remains unclear when it might be appropriate to start a
patient, not currently on regular maintenance therapy, on
combined LABA/ICS therapy rather than an ICS alone.
Studies that have compared combined LABA/ICS therapy to
ICS alone have provided conflicting results which might be
the result of phenotypic differences in the asthma of the
subjects included. For example, Pearlman in a 4-week study
comparing monotherapy with fluticasone to combination
therapy with salmeterol and fluticasone among patients on
short-acting b agonists alone, found better lung function and
symptom improvement with the combination.7 The subjects
included had, on average, asthma that was poorly controlled
as attested to by the need for more than two inhalations of
as needed b agonist per day and an average forced
expiratory volume in the first second (FEV1) of less than
70% predicted. In the recent GOAL study,3 subjects who had
not received maintenance ICS or LABA in the prior 6 months,
more frequently achieved well-controlled asthma after an
initial 12 weeks of salmeterol 50 mg and fluticasone 100 mg as
compared to fluticasone 100 mg alone, both inhaled twice a
day. Here again, subjects needed, on average, 1.8 inhala-
tions of rescue b agonist per day at baseline and the average
pre-bronchodilator FEV1 was less than 80%.
O’Byrne and colleagues compared combined LABA/ICS
controller therapy to ICS monotherapy in subjects previously
on rescue short-acting b agonists alone.8 Subjects receiving
the combination of formoterol 4.5mg and budesonide 100 mg
twice a day were no better in terms of symptom free days or
number of exacerbations as compared to subjects who were
randomized to receive budesonide 100 mg twice a day as the
only controller therapy over a period of 1 year. The average
FEV1 was 90% and subjects required, on average, less than
one inhalation per day of a rescue b agonist in the last
2 weeks of the baseline period.
These contrasting studies suggest that the degree of
airways obstruction and the need for rescue medication
might predict which patients, not currently on maintenancetherapy, but whose asthma is poorly controlled, might
respond better to combined LABA/ICS therapy and in whom
ICS as sole controller therapy might prove to be insufficient.
We carried out a secondary analysis of several clinical trials
to see whether we could identify factors which would allow
us to better target combined LABA/ICS therapy to those
patients whom would benefit most.Methods
We identified 2041 patients who were previously receiving
short-acting b agonists alone from the intent-to-treat
populations of five randomized controlled trials carried out
by Glaxo-Smith-Kline comparing the combination of salme-
terol 50 mg and fluticasone 100 mg bid to fluticasone 100 mg
bid as the only controller therapy. The majority (53%) were
patients from stratum 1 of the GOAL study.3 Inclusion
criteria for the studies were similar. Subjects had to be at
least 12 years of age, have asthma diagnosed more than 6
months ago and a maximum cumulative exposure to
cigarette smoking of 10 pack years. We excluded 327
subjects because their FEV1 was missing, or less than 60%.
The latter were excluded because we were primarily
interested in the role of combined maintenance therapy in
subjects with at most moderate airways obstruction. We
excluded a further 108 subjects for whom missing symptom
diary data made evaluation of asthma control, the outcome
under study, impossible leaving 1606 subjects for analysis.
The outcome of interest was achieving well-controlled
asthma as defined in the GOAL study in the last 2 weeks of
a 12-week follow-up. Well-controlled asthma was defined
each week as two or more of: (i) daytime symptomsp2 days
with a symptom score of41(1 was defined as ‘‘symptoms for
one short period during the day’’); (ii) use of rescue b
agonist on p2 days and p4 occasions; (iii) morning PEF
X80% predicted every day. Subjects had to remain in each
study for a minimum of 6 weeks. Information on a full 12
weeks was available for 96% of included subjects. For the
remaining 4%, the last 2 available weeks of observation
were used to determine whether well-controlled asthma
had been achieved.
Baseline predictors were collected prior to randomization
in each of the trials. For symptoms and rescue bronchodi-
lator use, information from the last 7 consecutive days of
run in prior to randomization was used. Baseline predictors
considered a priori were age, gender, smoking history (non-
smoker, current smoker, ex-smoker), race, body mass index
(BMI), duration of asthma, atopy, frequency of use of a
short-acting b agonist (SABA), daily symptoms and night
time awakenings in the prior week. Baseline information on
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categories: 6 months to less than 1 year, 1 year to less than 5
years, 5 years to less than 10 years, 10 years to less than 15
years and 15 years or more. Information on atopy was
obtained differently in the various studies. Atopy was
considered to be present if there was a positive answer to
a history of atopy, seasonal rhinitis, eczema or when there
was evidence in the medical chart of a raised serum IgE,
blood eosinophilia or positive allergy skin tests.
We used logistic regression to first explore each individual
variable-by-treatment interaction to better understand the
predictive ability of each potential clinical factor. Both the
continuous and categorized forms of the baseline variables
of interest were explored in separate models to ensure that
the most informative form for each variable was included in
the full multivariate model. Based on the distribution of
variables, clinical plausibility, and detection of significant
interactions with the treatment effect (combined salmeter-
ol and fluticasone versus fluticasone), variables were
dichotomized as shown in Table 1.Table 1 Baseline characteristics (N ¼ 1606).
N (%)
Age years
12–17 222 (14)
X18 1384 (86)
Gender male 657 (41)
Smoking
Current or former 436 (27)
Never 1170 (73)
Race
White 1265 (79)
Other 341 (21)
BMIX30 359 (22)
Duration of asthmaX10 years 890 (55)
Atopy 1113 (69)
PEFo80% predicted 782 (49)
FEV1o80% predicted 619 (39)
FEV1 reversibilityX20%
 586 (36)
Daily symptoms 1134 (71)
AwakeningsX2 nights/week 679 (42)
Daily mean rescue b2 agonist
useX2 doses per day
582 (36)
Missing for 226 (14%) subjects.
Table 2 Overall treatment effect.
Salmeterol and fluticasone,
N ¼ 790
Flu
Controlled Uncontrolled Co
N (%) N (%) N (
Treatment main effect 491 (62) 299 (38) 391
Odds ratio and 95% confidence interval were generated by univarBackwards elimination with multivariate logistic regres-
sion was used as the primary method for model selection.
Odds ratios for each level of the interaction were generated
with contrasts when significant (pp0.05). As a result of high
correlation between baseline predictors, multiple models
were identified. These models were compared and the best
model was chosen on the basis of statistical fit and clinical
relevance. Once a model was selected, treatment interac-
tions with morning peak flow (% predicted), FEV1
(% predicted) and % reversibility of FEV1 post bronchodilator
were added to the model. These assessments of baseline
pulmonary function were not included in the original
model selection exercise due to a significant amount of
missing data. SAS version 8.2 was used for all statistical
analyses.
Ethics approval was obtained prior to participation in
each trial at each participating institution.Results
A total of 1606 patients, 790 of whom received salmeterol
and fluticasone and 816 fluticasone as sole controller, were
included in the present analysis. Baseline characteristics for
all 1606 subjects are shown in Table 1. The mean percentage
predicted FEV1 was 83.9% (SD ¼ 14.06) and ranged from
60.0% to 147.6%. Overall as shown in Table 2, subjects were
80% more likely to achieve control with salmeterol and
fluticasone as compared to fluticasone alone (odds ratio 1.8,
95% CI 1.46–2.18).
Table 3 provides the distribution of the baseline char-
acteristics examined according to whether subjects
achieved or did not achieve well-controlled asthma at 12
weeks when randomized to receive salmeterol and flutica-
sone or fluticasone alone. Among the 890 subjects whose
asthma had been diagnosed 10 or more years ago, 268 of the
439 (61%) subjects randomized to combination therapy
achieved control as compared to 186 of 451 (41%) of
subjects randomized to receive fluticasone alone. This
interaction between treatment duration and treatment
group was statistically significant (p ¼ 0.016). The results
in Table 3 indicate that asthma duration of 10 years or longer
was present in 55% of subjects controlled on combination
therapy, 57% uncontrolled on combined therapy, 48%
controlled on fluticasone alone and 62% uncontrolled on
fluticasone alone. None of the interactions by baseline
pulmonary function were statistically significant. Of note,
information on FEV1 bronchodilator reversibility was missing
for 226 (14%) subjects.ticasone alone, N ¼ 816 Odds ratio 95% CI
ntrolled Uncontrolled
%) N (%)
(48) 425 (52) 1.79 (1.46, 2.18)
iate logistic regression.
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Table 3 Baseline predictors of treatment advantage.
Salmeterol and fluticasone, N ¼ 790 Fluticasone alone, N ¼ 816 Treatment
interaction
p-valueControlled
N ¼ 491
Uncontrolled
N ¼ 299
Controlled
N ¼ 391
Uncontrolled
N ¼ 425
N (%) N (%) N (%) N (%)
AgeX18 425 (87) 256 (86) 331 (85) 372 (88) 0.276
Gender: male 206 (42) 118 (39) 146 (37) 187 (44) 0.067
Smokers former and current 121 (25) 94 (31) 89 (23) 132 (31) 0.705
Race: non-white 102 (21) 70 (23) 78 (20) 91 (21) 0.795
BMIX30 95 (19) 77 (26) 73 (19) 114 (27) 0.916
Asthma durationX10 years 268 (55) 171 (57) 186 (48) 265 (62) 0.016
Atopy: yes 363 (74) 191 (64) 273 (70) 286 (67) 0.105
Daily symptoms 328 (67) 235 (79) 237 (61) 334 (79) 0.374
AwakeningsX2 nights 173 (35) 164 (55) 138 (35) 204 (48) 0.202
Mean rescueb2X2 doses/day 164 (33) 130 (43) 105 (27) 183 (43) 0.197
PEFo80% pred. 235 (48) 160 (54) 159 (41) 228 (54) 0.187
FEV1o80% pred. 184 (37) 126 (42) 121 (31) 188 (44) 0.073
ReversibilityX20% 190 (39) 107 (36) 133 (34) 156 (37) 0.412
Separate logistic regression models were used to generate p-values for treatment-by-predictor interactions.
Table 4 Effect of treatment according to asthma duration.
Salmeterol and fluticasone,
N ¼ 790
Fluticasone alone, N ¼ 816 Odds
ratio
95% CI
Controlled
N ¼ 491
Uncontrolled
N ¼ 299
Controlled
N ¼ 391
Uncontrolled
N ¼ 425
N (%) N (%) N (%) N (%)
Asthma durationX10 years 268 (55) 171 (57) 186 (48) 265 (62) 2.2 (1.71, 2.92)
Asthma durationo10 years 223 (45) 128 (43) 205 (52) 160 (38) 1.4 (1.01, 1.84)
Odds ratios and 95% confidence intervals were generated from the final selected logistic regression model.
P. Ernst et al.80For subjects reporting duration of asthma of 10 years
or more, there was a 2.2-fold advantage (95% CI 1.71–2.92)
for combination therapy in achieving asthma control by
12 weeks of therapy. The difference between the two
treatment options was less for those subjects with a
shorter duration of asthma (odds ratio 1.4, 95% CI
1.01–1.84) (Table 4).Discussion
We combined the results of available randomized clinical
trials comparing combination therapy with salmeterol and
fluticasone to fluticasone as sole controller therapy, in order
to identify factors which might help predict which patients,
not recently on regular controller therapy for asthma, would
benefit most from combined LABA/ICS treatment as com-
pared to ICS therapy alone. Overall, the patients were 1.8
times more likely to achieve well-controlled asthma within
12 weeks with combination therapy than with fluticasone
alone. The benefit was more pronounced among subjects
reporting a duration of asthma of 10 years or more (2.2
times more likely to achieve asthma control) as compared tothose with a shorter reported duration of disease (1.4 times
more likely to achieve control with combination therapy).
None of the other factors examined including symptom
frequency or severity, rescue b-agonist use, severity of lung
function impairment or degree of reversibility, was able to
distinguish subjects who would benefit more than average
from combination LABA/ICS treatment as compared to ICS
treatment alone. To ensure the validity of our findings, all of
the potential predictors of response were defined a priori
and were tested as formal statistical interactions.9
By pooling the results of a number of studies evaluating
the role of combination therapy as an initial treatment
approach, this analysis has identified both a biologically
plausible and easy to apply clinical predictor of benefit from
initial combination controller therapy—duration of asthma.
The effect size is substantial and likely to be appreciated by
patients. Given the number of participants, we consider it
unlikely that other predictors have been missed.
An argument can still be made that a 3-month assessment
is inadequate to fully evaluate the benefits of inhaled
corticosteroids alone, particularly without dose escalation.
Conversely it remains possible that several of the factors
examined might better predict a preferential response to
ARTICLE IN PRESS
Initial maintenance therapy for asthma 81combination therapy over a longer period of time. Overall,
however, it is not unreasonable for physicians and their patients
to expect a substantial improvement in their condition within 3
months of initiating regular controller therapy.
Greater efficacy of combination LABA/ICS therapy in
patients with more prolonged disease is consistent with
studies suggesting that the benefits with ICS as sole
controller therapy are most pronounced in the early natural
history of asthma.10,11 Greater benefit of combination
therapy is also consistent with the notion that the primary
effect of the LABA component is on the smooth muscle cell,
which increases in amount with more prolonged duration of
asthma.12 The increased smooth muscle mass may be
indicative of the greater importance of smooth muscle
contraction in the pathogenesis of symptoms of poor asthma
control in individuals with a longer duration of disease, and
hence the benefit of combination therapy with a LABA.
Alternatively, there is some evidence that the increased
matrix in the airway wall in asthma, which also increases
with increased asthma duration,13 contributes to the
persistence of airway inflammation and airways hyperre-
sponsiveness by facilitating retention of cytokines and
chemokines and thus inflammatory cell influx.14 This in turn
predicts the need for a greater corticosteroid action to
reduce proinflammatory cytokine production in long stand-
ing disease, and LABAs promote corticosteroid action.15
The presence of airflow limitation, especially if only
partially reversible, is thought to indicate remodeling.13,16
Somewhat surprisingly, in our data neither the degree of
airflow limitation nor the degree of reversibility was
associated with a differential response to combination
LABA/ICS therapy. Although a large bronchodilator response
may indicate patients at a higher risk of exacerbations17 and
hence expected to be predictive of a better response to dual
controller therapy, this benefit was not observed in our
study; perhaps because these data were not collected in all
enrolled subjects. As we limited our analysis to subjects
with an FEV1 of at least 60% predicted we may have missed a
preferential response to combination LABA/ICS therapy
among subjects with more severe airways obstruction.
In conclusion, the results of this analysis suggest that
duration of disease is a practical tool physicians can use to
predict that asthmatic patients, not currently on sustained
controller therapy, will derive greater benefit from a
combination of inhaled steroids and long-acting b agonists
than subjects with a shorter duration of asthma. It would be
worthwhile to re-examine this question in completed trials
of other combinations of an inhaled corticosteroid and a
long-acting b-agonist.
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